Boston, MA – October 1, 2025 – Biogen Inc. (NASDAQ: BIIB) saw its stock surge by an impressive 9.02% today, propelled by a wave of promising advancements in its Alzheimer's disease drug testing pipeline. The significant leap signals renewed investor confidence and marks a potentially pivotal moment in the battle against
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 8.6% in the afternoon session after the stock's positive momentum continued as the White House revealed plans to launch a website for consumers to purchase drugs from manufacturers at a discount, providing clarity for the pharmaceutical industry on future pricing policies. The positive sentiment was bolstered by news that competitor Pfizer had already secured a deal to lower some of its U.S. drug prices. Following this, Eli Lilly confirmed it is in "active discussions with the administration to further expand patient access." This development has eased investor concerns about potential government-imposed price controls, which had created uncertainty for the sector. The prospect of reaching favorable agreements is now seen as an opportunity for major drugmakers, leading to a rally across the industry.
Shares of global pharmaceutical company Merck (NYSE:MRK)
jumped 7.7% in the afternoon session after the Trump administration announced a new program to sell drugs directly to consumers.
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
As the third quarter of 2025 draws to a close, the financial markets are abuzz with the exceptional performances of several S&P 500 companies. While official data is still being compiled, preliminary assessments and prevailing market trends suggest a cohort of innovative giants and agile disruptors have delivered significant
As the U.S. government shutdown deadline looms on September 30, 2025, financial markets are bracing for impact, with gold prices exhibiting strong upward momentum, driven by intense safe-haven demand. While a specific peak above US$3,860 per ounce has not been officially confirmed as of this exact moment,
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
New York, NY – September 30, 2025 – Shares of pharmaceutical giant Pfizer (NYSE: PFE) experienced a dramatic decline today, making it one of the market's bottom performers, following an unexpected and significant setback in its highly anticipated obesity drug pipeline. The news has sent ripples through the biopharmaceutical sector, highlighting the
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing agreement reached between the White House and a major pharmaceutical player, Pfizer (NYSE: PFE). This development has been widely interpreted by investors as
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 5.5% in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
The global financial markets are currently navigating a tumultuous period, largely driven by an escalating wave of new trade tariffs. As of September 30, 2025, a series of aggressive trade policy decisions, primarily initiated by the United States under President Donald Trump's administration, have sent significant ripples across stock futures,
